![1]()
News
No serious CV risks for elderly after Pfizer COVID-19 vaccine
December 2, 2021
A French study adds to other evidence that the Pfizer mRNA COVID-19 vaccine does not increase the risk for serious cardiovascular adverse events in elderly individuals.
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
![1]()
News
Bedside frailty assessment can determine when CPR will be nonbeneficial
December 1, 2021
How does frailty impact survival after inpatient cardiac arrest in older adults?
![1]()
News
Optimizing perioperative cardiac risk assessment and management for noncardiac surgery
November 30, 2021
What is the sum of evidence supporting perioperative cardiac risk assessment and risk reduction?
News
Predicting cardiac shock mortality in the ICU
November 23, 2021
Including biventricular dysfunction as assessed using transthoracic echocardiography improves clinical risk stratification.
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
Early rhythm control in atrial fibrillation (EAST-AFNET trial)
November 17, 2021
Is rhythm control superior to rate control in treating early atrial fibrillation (AFib)?
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
![1]()
News
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
November 17, 2021
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
